HAVCR2 and neoplasm: Furthermore, sncRNAs and small-molecule inhibitors targeting other immune checkpoints, such as LAG-3 and TIM-3, are under active investigation in both preclinical studies and clinical trials, offering promising potential for expanded applications in tumor immunotherapy (125, 134).